RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
  CAD
  CHF
  Clinical Trials
  Hypertension
  Myocardial Infarction
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
The CHARISMA trial Clinical Trials Channel

subscribe to Clinical Trials newsletter
Latest Research : Cardiology : Clinical Trials

   EMAIL   |   PRINT
Clopidogrel and aspirin combination fails to show long term beneficial affects in stable vascular patients

Mar 18, 2006 - 2:17:00 AM , Reviewed by: Rashmi Yadav
“Patients taking Clopidogrel (Plavix®) should not stop taking the anti-clotting drug without first consulting their physician."

 
[RxPG] While the CHARISMA trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance) results have shown no benefit overall of the combination of Clopidogrel and aspirin in the long term in stable vascular patients, and some indication of harm in patients in primary prevention, the ESC would like to remind patients that dual antiplatelet therapy is an essential, approved and recommended therapy for one year in patients post ACS without ST-segment elevation, and for at least six months post stenting.

“Patients taking Clopidogrel (Plavix®) should not stop taking the anti-clotting drug without first consulting their physician,” said ESC spokesperson on Acute Coronary Syndromes, Professor Freek Verheugt from Radboud University Medical Center, Nijmegen, Netherlands. “Patients who stop taking Clopidogrel without seeking the advice of their doctor may be putting themselves in grave danger.”

For more information, please see current ESC guidelines for “Percutaneous Coronary Intervention” (1) (http://www.escardio.org/knowledge/guidelines/PCI-Guidelines.htm) and “Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation” (2) (http://www.escardio.org/knowledge/guidelines/Management_ACS_without_persistent_ST-segment_elevation.htm).

The CHARISMA trial was presented at the Annual Scientific Sessions of the American College of Cardiology in March 2006 and simultaneously published on the website of The New England Journal of Medicine (http://content.nejm.org/).

The European Society of Cardiology (ESC)

The ESC represents more than 45,000 cardiology professionals across Europe and the Mediterranean. Its mission is to improve the quality of life of the European population by reducing the impact of cardiovascular disease.

The ESC achieves this through a variety of scientific and educational activities including the coordination of: clinical practice guidelines, education courses and initiatives, pan-European surveys on specific disease areas and the ESC Annual Congress, the largest medical meeting in Europe. Furthermore, the ESC promotes cardiovascular disease prevention messages to the general public, most notably during its annual 'For Your Heart's Sake' event, a fun yet educational event offering risk assessment and prevention advice, held in parallel to the Congress each year.




Publication: The CHARISMA trial was presented at the Annual Scientific Sessions of the American College of Cardiology in March 2006 and simultaneously published on the website of The New England Journal of Medicine
On the web: http://www.escardio.org/ 

Advertise in this space for $10 per month. Contact us today.


Related Clinical Trials News
Aspirin of no use in primary prevention of cardiovascular events- POPADAD trial
Adipose-derived stem cells as a therapy for cardiovascular diseases ?
Pre hypertension best managed by early pharmacological intervention
Patients should not discontinue clopidogrel without consultation
Clopidogrel and aspirin combination fails to show long term beneficial affects in stable vascular patients
Bluhm Cardiovascular Institute Surgeons Implant Heart Pump in Comparative Study of Two Devices
Ground-breaking heart stem cell trial (REGENERATE) now underway

Subscribe to Clinical Trials Newsletter

Enter your email address:


 Additional information about the news article
Reference:
(1) European Heart Journal 23, 1809–1840: 2002; Michel E. Bertrand, Chair, Maarten L. Simoons, Keith A. A. Fox, Lars C. Wallentin, Christian W. Hamm, Eugene McFadden, Pim J. De Feyter, Giuseppe Specchia, Witold Ruzyllo, “Acute Coronary Syndromes in Patients Presenting without persistente ST-segment elevation (Management of).”

(2) European Heart Journal 26, 804-847: 2005; S. Silber (Chairperson), P. Albertsson, F. Fernandez-Avilès, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J-E. Nordrehaug, W. Ruzyllo, P. Urban, G. W. Stone, W. Wijns, “Percutaneous Coronary Interventions (Guidelines for).”
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)